Poniard Pharmaceuticals Inc
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplat… Read more
Poniard Pharmaceuticals Inc (PARD) - Total Assets
Latest total assets as of September 2011: $7.74 Million USD
Based on the latest financial reports, Poniard Pharmaceuticals Inc (PARD) holds total assets worth $7.74 Million USD as of September 2011.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Poniard Pharmaceuticals Inc - Total Assets Trend (1988–2010)
This chart illustrates how Poniard Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Poniard Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2010)
Poniard Pharmaceuticals Inc's total assets of $7.74 Million consist of 44.8% current assets and 55.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $49.00K | 0.4% |
| Intangible Assets | $6.38 Million | 54.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1988–2010)
This chart illustrates how Poniard Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Poniard Pharmaceuticals Inc's current assets represent 44.8% of total assets in 2010, a decrease from 77.5% in 1988.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2010, down from 69.2% in 1988.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 54.0% of total assets, an increase from 0.0% in 1988.
- Asset Diversification: The largest asset category is intangible assets at 54.8% of total assets.
Poniard Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Poniard Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Poniard Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Poniard Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Poniard Pharmaceuticals Inc is currently not profitable relative to its asset base.
Poniard Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.76 | 1.96 | 4.47 |
| Quick Ratio | 0.76 | 1.96 | 4.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-727.00K | $ 11.93 Million | $ 42.30 Million |
Poniard Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Poniard Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.10 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -77.8% |
| Total Assets | $11.64 Million |
| Market Capitalization | $0.92 USD |
Valuation Analysis
Below Book Valuation: The market values Poniard Pharmaceuticals Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Poniard Pharmaceuticals Inc's assets decreased by 77.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Poniard Pharmaceuticals Inc (1988–2010)
The table below shows the annual total assets of Poniard Pharmaceuticals Inc from 1988 to 2010.
| Year | Total Assets | Change |
|---|---|---|
| 2010-12-31 | $11.64 Million | -77.80% |
| 2009-12-31 | $52.44 Million | -37.74% |
| 2008-12-31 | $84.23 Million | -19.89% |
| 2007-12-31 | $105.14 Million | +52.23% |
| 2006-12-31 | $69.07 Million | +582.89% |
| 2005-12-31 | $10.11 Million | -63.14% |
| 2004-12-31 | $27.44 Million | -23.13% |
| 2003-12-31 | $35.69 Million | +37.31% |
| 2002-12-31 | $25.99 Million | -49.06% |
| 2001-12-31 | $51.03 Million | -20.84% |
| 2000-12-31 | $64.46 Million | +209.89% |
| 1999-12-31 | $20.80 Million | -35.80% |
| 1998-12-31 | $32.40 Million | -10.74% |
| 1997-12-31 | $36.30 Million | +77.07% |
| 1996-12-31 | $20.50 Million | +10.81% |
| 1995-12-31 | $18.50 Million | -7.50% |
| 1994-12-31 | $20.00 Million | -32.89% |
| 1993-12-31 | $29.80 Million | +61.08% |
| 1992-12-31 | $18.50 Million | -12.32% |
| 1991-12-31 | $21.10 Million | -17.90% |
| 1990-12-31 | $25.70 Million | -49.41% |
| 1989-12-31 | $50.80 Million | +44.73% |
| 1988-12-31 | $35.10 Million | -- |